Page 1

Q1 Interim report January 1 - March 31 , 2021 January - March 2021 Net revenue for the period was SEK 87.7 million ( 83.7 ) EBITDA for the period was SEK 8.9 million ( 5.4 ) EBITA for the period was SEK 6.9 million ( 3.4 ) Profit / loss for the period was SEK 2.5 million ( -2.5 ) Basic earnings per share for the period amounted to SEK 0.02 ( -0.02 ) Orders received for the period totaled SEK 91.7 million ( 137.3 ) Operating cash flow for the period was SEK -1.3 million ( 8.7 ) >> >> >> >> >>> >> >> SEK THOUSANDS Net revenue EBITDA EBITDA margin , % ЕВІТА EBITA margin , % Profit / loss before tax ( EBT ) Profit / loss for the period Basic earnings per share ( SEK ) ¹ Net debt - to - EBITDA² Notes 2021 Jan - Mar 87,737 8,864 10.1 % 6,947 7.9 % 3,449 2,515 0.02 2.6 1 Earnings per share were adjusted to take into account the outcome of warrants in series 2019/2021 in February 2021 . 2 EBITDA in the key performance indicator Net debt - to - EBITDA is based on a rolling 12 - month period . ADDvise 2020 Jan - Mar Change 5 % 65 % 83,704 5,384 6.4 % 3,365 4.0 % -2,085 -2,474 -0.02 6.1 106 % 265 % 202 % ADDvise Group AB ( publ ) , company reg . no . 556363-2115 , Grev Turegatan 3 , SE - 114 46 Stockholm , Sweden Telephone +46 ( 0 ) 8 128 766 00 , e - mail : info@addvisegroup.se , website www.addvisegroup.se Rolling 12 months Apr 2020 Mar 2021 362,520 49,704 13.7 % 41,729 11.5 % 23,390 19,626 0.16 2.6 2020 Jan - Dec 358,487 46,224 12.9 % 38,147 10.6 % 17,857 14,637 0.12 3.3 Change 1 % 8 % The ADDvise Group in brief ADDvise Group AB ( publ ) is a leading supplier of equipment to healthcare and research facilities . The Group consists of approximately ten subsidiaries organized into two business areas , Lab and Healthcare . Sales are global . The Group has a clear acquisition strategy with the aim of raising shareholder value and expanding the business - both geographically and product - wise . 9 % 31 % 34 %